Mabwell (shanghai) Bioscience Co., Ltd. Class ASSE: 688062

"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026

Aug 31, 2026 · Issued by Mabwell (shanghai) Bioscience Co., Ltd. Class A via Shanghai Stock Exchange

Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Mabwell (shanghai) Bioscience Co., Ltd. Class A

Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab InjectionsAug 9
"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Voluntary Disclosure of the Approval by the National Medical Products Administration of the Clinical Trial Application for 9MW5211 InjectionJul 16
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public OfferingJun 26
Announcement on Voluntary Disclosure of Clinical Trial Applications for 9MW5211 Injection Approved by China NMPAJun 25

All Mabwell (shanghai) Bioscience Co., Ltd. Class A news releases